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Abstract  15 
PRRS control is hampered by the inadequacies of existing vaccines to combat the extreme 16 
diversity of circulating viruses. Since immune clearance of PRRSV infection may not be 17 
dependent on the development of neutralising antibodies and the identification of broadly-18 
neutralising antibody epitopes have proven elusive we hypothesised that conserved T cell 19 
antigens represent potential candidates for development of a novel PRRS vaccine. Previously 20 
we had identified the M and NSP5 proteins as well-conserved targets of polyfunctional CD8 21 
and CD4 T cells. To assess their vaccine potential, peptides representing M and NSP5 were 22 
encapsulated in hydrophobically-modified chitosan particles adjuvanted by incorporation of a 23 
synthetic multi-TLR2/TLR7 agonist and coated with a model B cell PRRSV antigen. For 24 
comparison, empty particles and adjuvanted particles encapsulating inactivated PRRSV-1 25 
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were prepared. Vaccination with the particulate formulations induced antigen-specific 26 
antibody responses, which were most pronounced following booster immunisation.  M and 27 
NSP5-specific CD4, but not CD8, T cell IFN-γ reactivity was measurable following the 28 
booster immunisation in a proportion of animals vaccinated with peptide-loaded particles. 29 
Upon challenge, CD4 and CD8 T cell reactivity was detected in all groups, with the greatest 30 
responses being detected in the peptide vaccinated group but with limited evidence of an 31 
enhanced control of viraemia. Analysis of the lungs during the resolution of infection showed 32 
significant M/NSP5 specific IFN-γ responses from CD8 rather than CD4 T cells. Vaccine 33 
primed CD8 T cell responses may therefore be required for protection and future work should 34 
focus on enhancing the cross-presentation M/NSP5 to CD8 T cells.  35 
Keywords: porcine reproductive and respiratory syndrome virus, chitosan particles, vaccine 36 
formulation, T cell,  37 
Introduction 38 
Porcine reproductive and respiratory syndrome (PRRS) is one of the most important pig 39 
diseases worldwide. The causative PRRS virus (PRRSV) is rapidly evolving and there is an 40 
urgent need for the development of safer and more efficacious vaccines to improve PRRS 41 
control. Efforts to develop improved vaccines have focused primarily on the structural 42 
envelope glycoproteins but these have met with limited success and thus alternative 43 
approaches are required (Murtaugh and Genzow, 2011; Renukaradhya et al., 2015). While the 44 
immunological mechanisms underlying protection against PRRSV remain to be fully defined, 45 
there is evidence to suggest that cell-mediated immune responses play an important role 46 
(Murtaugh and Genzow, 2011; Zuckermann et al., 2007). Indeed, T cells are crucial to the 47 
control of many viruses through cytolysis of infected cells and cytokine secretion. Since 48 
clearance of PRRSV infection may not be dependent on neutralising antibodies, we 49 
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hypothesised that conserved PRRSV T cell antigens should be considered as an integral 50 
component of any next-generation PRRSV vaccine. Through proteome-wide peptide library 51 
screening, we identified both the structural matrix (M) protein and the non-structural protein 52 
5 (NSP5) from PRRSV genotype 1 (PRRSV-1) as well conserved targets of T cell immunity 53 
(Mokhtar et al., 2016), which warranted further evaluation of their vaccine potential.  54 
Amongst the range of vaccine delivery systems being developed to induce T cell mediated 55 
immunity to defined antigens, one strategy which possesses a number of desirable features is 56 
the use of nano- or micro-particles to deliver vaccine antigen to dendritic cells (DCs).  Both 57 
antigens in protein or plasmid DNA form can be encapsulated inside or coated to the surface 58 
of biodegradable particles which allows for sustained release after administration, increasing 59 
the bioavailability and decreasing the degradation (Bivas-Benita et al., 2004; Shen et al., 60 
2006). The efficient internalisation of the particle is a distinct advantage and if taken up by 61 
dendritic cell (DC) allows the cargo of antigen to be potentially processed via the MHC class 62 
I or II presentation pathways (Hirosue et al., 2010). In addition, particles can carry molecular 63 
adjuvants thus delivering the appropriate stimulatory signals together with the antigen to 64 
individual DC. Particulate vaccines have been evaluated in the context of PRRSV, with killed 65 
PRRSV encapsulated inside poly(lactic, glycolic acid) (PLGA) particles and administered 66 
intranasally to pigs resulting in enhanced antibody and T cell responses that translated to 67 
cross-protective immunity (Binjawadagi et al., 2014a; Binjawadagi et al., 2014b; Dwivedi et 68 
al., 2013).  Amongst the available polymers used to produce particles, chitosan has a number 69 
of attractive features for vaccine delivery. Chitosan and its derivatives are abundantly 70 
expressed biological polysaccharides which readily form particles (Jayakumar et al., 2010). 71 
Chitosan may offer an inherent adjuvant effect through binding the innate immune sensor, 72 
Toll-like receptor 4 (TLR4), and has been shown to bind specifically to mannose receptors 73 
expressed on DCs (Villiers et al., 2009).  This study therefore evaluated the immunogenicity 74 
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of chitosan particles loaded with M and NSP5 antigens in comparison to inactivated PRRSV-75 
1. Since it has been shown that targeting multiple TLRs augments vaccine immunogenicity 76 
and efficacy (Kasturi et al., 2011; Querec et al., 2006), particles were adjuvanted by 77 
incorporation of the synthetic multi-TLR2/TLR7 agonist Adilipoline™.  78 
Materials and methods 79 
Ethics statement 80 
All work was approved by the APHA Ethics Committee and conducted in accordance with 81 
the UK Animals (Scientific Procedures) Act 1986 under Project Licence numbers PPL 82 
70/7057 and 70/7209.  83 
PRRS viruses, peptides and proteins 84 
The PRRSV-1 subtype 1 strains Olot/91 and 215-06 were propagated and titrated in MARC-85 
145 cells and porcine alveolar macrophages, respectively (Mokhtar et al., 2014; Morgan et 86 
al., 2013). For the vaccine formulation, PRRSV-1 Olot/91 was grown in serum free RPMI-87 
1640 medium, semi-purified and concentrated using a 300kDa MicroKros Filter Module 88 
(Spectrum Labs, Breda, The Netherlands) and inactivated by incubation with a 1:1000 89 
dilution of β-propriolactone (Sigma-Aldrich, Poole, UK) at 37°C for 2 hours with continuous 90 
shaking. Inactivation was confirmed by virus titration. A recombinant fusion protein, EM4, 91 
consisting of the GP5 ectodomain (MSSTYQYIYNLTICELNGTDWLSNHA, that 92 
corresponds to amino acids 37-61 of GP5, except the terminal methionine and alanine 93 
residues that were added for cloning purposes) fused directly to the C-terminal region of the 94 
M protein (MDAHHVKSAAGLHSIPASGNRAYAVRKPGLTSVNGTLVPGLRSL, 95 
corresponding to amino acids 112-151 of M protein except the two first residues that were 96 
included for cloning purposes) from PRRSV-1 Olot/91 was expressed by a recombinant 97 
baculovirus in Sf9 cells. EM4 was purified from infected cell lysates by Ni2+ affinity 98 
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chromatography, dialysed and detected by western blotting. Overlapping 20mer peptides, 99 
offset by 10 amino acids, encompassing the entire M and NSP5 proteins from PRRSV-1 100 
Olot/91 strain were synthesised (Mimotopes, Heswall, UK) and reconstituted in sterile 101 
DMSO (Sigma-Aldrich, Poole, UK).  102 
Particulate PRRSV vaccine formulations 103 
Three chitosan-based particulate formulations were prepared: (1) Inactivated PRRSV-1 104 
Olot/91 loaded particles (Virus-P), (2) M and NSP5 peptide loaded and EM4-coated particles 105 
(Peptide-P) and (3) control empty particles (Empty-P). For each vaccine dose of particles, 106 
50mg of octanyl-chitosan (chitosan from Heppe Medical Chitosan GmbH, Halle, Germany) 107 
dissolved in chloroform was mixed with the following: Virus-P - 50µg Adilipoline™ 108 
(Invivogen, Source Bioscience, Nottingham, UK), 6x107 TCID50 equivalent inactivated 109 
PRRSV-1 Olot/91; Peptide-P - 50µg Adilipoline, 100µg of each 20mer M and NSP5 110 
peptides; and Empty-P - sterile deionised water. 15% PVA was added to each preparation and 111 
homogenised for 1 minute followed by probe sonication for 2 minutes (amplitude 17 112 
microns). The mixtures were then added drop-wise to 1% PVA whilst homogenising for 4 113 
minutes. Following removal of solvent by evaporation, the following were adsorbed onto the 114 
surface of the particles by adding drop-wise whilst on a magnetic stirring block: Virus-P - 115 
50µg Adilipoline/dose; Peptide-P - 50µg Adilipoline and 200µg EM4 protein/dose and 116 
Empty-P were left untreated. All vaccine formulations were diluted to 4ml per dose with 117 
sterile water. The surface charge of particles was measured using a Zeta Sizer 3000 (Malvern 118 
Instruments, Malvern, UK) and particle morphology and size assessed using scanning 119 
electron microscopy (Walters et al., 2015). To assess loading and coating efficiencies aliquots 120 
of each formulation were centrifuged at 14000 rpm for 5 min and supernatants were 121 
harvested and stored at -80°C until analysed. ELISA and biochemical assay analyses of 122 
particle-free supernatants were conducted to determine the efficiency of virus (ELISA) or 123 
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peptide (fluorometric o-phthalaldehyde assay) encapsulation and coating with EM4 protein 124 
(ELISA). Absorption of EM4 to particle surfaces was additionally assessed by flow 125 
cytometric staining of particles (Walters et al., 2015).  Further details of these assays are 126 
provided in Supplementary Materials. 127 
In vitro assessment of the innate immunostimulatory properties of particulate PRRSV 128 
vaccine formulations 129 
To assess stimulation of monocytes and DCs with particles, heparinised blood was collected 130 
from PRRSV antibody negative Large White/Landrace cross-bred pigs 6 months of age. 131 
Peripheral blood mononuclear cells (PBMC) were isolated by density gradient centrifugation 132 
(Franzoni et al., 2013a). Monocytes and dendritic cells (DCs) were enriched separately from 133 
PBMC by magnetic bead based sorting (Franzoni et al., 2014). In brief, PBMC were 134 
incubated with human CD14 microbeads (Miltenyi Biotec, Bisley, UK), and applied to a LD 135 
column (Miltenyi Biotec). The negative flow through (CD14-) fraction were sequentially 136 
stained with 10μg/108 cells of mouse anti-porcine CD172a mAb (clone 74-22-15A, 137 
Washington State University Monoclonal Antibody Center (WSUMAC), Pullman, USA) and 138 
mouse IgG microbeads (Miltenyi Biotec). CD172a+ cells were enriched using an LS column 139 
(Miltenyi Biotec). To obtain a purer monocyte population the CD14+ fraction was also 140 
enriched using an LS column. CD172a+ (DC) and CD14+ (monocytes) fractions were eluted 141 
and adjusted to 4x106 cells/ml in RPMI-1640 medium with 10% FBS (cRPMI), which was 142 
further supplemented for DC cultures with 20ng/ml of recombinant porcine IL-3 (Franzoni et 143 
al., 2014). Cells were seeded 50µl/well in 96 well round bottom plates and stimulated with 144 
titrations of Virus-, Peptide- or Empty-P. Unstimulated and Adilipoline (10µg/ml) stimulated 145 
cells were included as negative and positive controls respectively. After 18 hours culture at 146 
37oC, cytokines were quantified in cell-free culture supernatants using commercial ELISA 147 
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kits for porcine IL-8, IL-10 and IL-12 (all R&D Systems) and type I IFN bioactivity reporter 148 
gene assay (Franzoni et al., 2014).  149 
Immunisation of pigs with particulate PRRSV vaccine formulations and challenge with 150 
PRRSV 151 
Eighteen PRRSV antibody negative Large White/Landrace male piglets 8 weeks of age were 152 
randomly assigned to three groups (n=6) which were vaccinated subcutaneously behind each 153 
ear with 2ml of either the Virus-P, Peptide-P or Empty-P formulations. An identical booster 154 
vaccination was given on day 21 post-primary vaccination. Animals were challenged 155 
intranasally on day 42 post-primary vaccination with 105 TCID50 of PRRSV-1 215-06 and 156 
monitored for clinical scores and rectal temperatures until the end of the study, day 63 post-157 
primary vaccination (day 21 post-challenge) (Morgan et al., 2013). Heparinised blood and 158 
serum samples were collected at weekly intervals during the study to analyse immune 159 
responses. RNA was isolated from EDTA blood samples collected every 2-3 days from day -160 
2 post-challenge using the QIAamp RNA Blood Mini Kit (QIAGEN, Crawley UK) and 161 
PRRSV RNA measured using the QuantiTect® Probe RT-PCR kit (QIAGEN)((Frossard et 162 
al., 2012). PRRSV genome copy numbers were interpolated using a standard PRRSV-1 163 
nucleocapsid gene (ORF7) RNA prepared from PRRSV-1 215-06 (Morgan et al., 2013).  164 
Measurement of PRRSV-specific antibody responses 165 
EM4 specific serum antibody responses were analysed by ELISA. ELISA plates (MAXISorb, 166 
Nunc) were coated overnight at 4°C with 1µg/ml recombinant EM4 protein in carbonate-167 
bicarbonate buffer. After washing and blocking in BSA, serum, diluted 1 in 100, was added 168 
for 1h at room temperature (RT). After washing, goat anti-porcine IgG-HRP antibody 169 
(Jackson ImmunoResearch, Stratech Scientific Limited, Newmarket, UK) diluted 1/20,000 170 
was added for 1h at RT. Plates were washed and developed by addition of TMB substrate 171 
8 
 
(Sigma). PRRSV N protein-specific antibody responses were analysed using the INgezim 172 
PRRS 2.0 ELISA (Ingenasa).  PRRSV neutralizing antibody titres in serum samples were 173 
determined as described (Weesendorp et al., 2013) with minor modifications. Serial 2-fold 174 
dilutions of heat-inactivated sera were incubated with 400 TCID50 of PRRSV-1 Olot/91 for 175 
1hr at 37oC before addition of MARC-145 cells (5x103 cells/well). After 72 hours incubation, 176 
infection was assessed by immunoperoxidase staining and antibody titres calculated as log2 of 177 
the reciprocal serum dilution that fully neutralized viral replication in 50% of the wells 178 
(ND50). 179 
Measurement of antigen-specific T cell responses  180 
PBMC were suspended in cRPMI at a density of 1x107/ml and seeded 100µl/well in 96 well 181 
round bottom plates (Costar, Fisher Scientific) and stimulated with 100µl PRRSV-1 Olot/91 182 
at a multiplicity of infection (MOI) of 0.1, M and NSP5 peptide pools with each constituent 183 
peptide at 1µg/ml. Negative controls were PBMC incubated in cRPMI alone or with mock-184 
virus supernatants. Virus and peptide stimulated PBMC were incubated before the addition 185 
and further incubation of brefeldin A (0.1µl/well) (GolgiPlug, BD Biosciences) as described 186 
(Franzoni et al., 2013b).  After incubation, PBMC were stained with Zombie Near Infra-Red 187 
Fixable Viability Kit (Biolegend, London, UK), CD4-PerCP-Cy5.5 (clone 74-12-4, BD 188 
Biosciences) and CD8α-PE (clone 76-2-11, BD Biosciences) mAbs, fixed/permeabilized in 189 
CytoFix/CytoPerm solution (BD Biosciences), stained with IFN-γ-Alexa Fluor 647 (clone 190 
CC302, AbD Serotec) and TNF-α-Brilliant Violet 421 (clone MAb11, Biolegend) mAbs or 191 
the respective isotype controls (Alexa Fluor 647 mouse IgG1 isotype control, AbD Serotec, 192 
and Brilliant Violet 421 mouse IgG1 isotype control, Biolegend) and analysed using a 193 
MACSQuant Analyzer flow cytometer (Franzoni et al., 2013a).  194 
On day 21 post-challenge, animals were euthanized and bronchoalveolar lavage fluid (BALF) 195 
collected (Morgan et al., 2013). BALF cellularity was analysed directly using a volumetric 196 
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MACSQuant Analyzer flow cytometer. The T cell composition of BALF was determined by 197 
staining with CD3-FITC (clone BB23-8E6-8C8; BD Biosciences), CD4-PerCP-Cy5.5 (clone 198 
74-12-4) and CD8α-PE (clone 76-2-11) mAbs for 30 minutes at 4oC. Cells were washed 199 
twice in PBS and analysed by flow cytometry. To assess antigen-specific T cell responses, 200 
mononuclear cells were isolated by density gradient centrifugation, stimulated with PRRSV-1 201 
Olot/91 or a pool of M/NSP5 peptides and IFN-γ and TNF-α expression by CD4 and CD8 T 202 
cells analysed as described above.   203 
Statistical analysis 204 
GraphPad Prism 6.01 (GraphPad Software, La Jolla, USA) was used for graphical and 205 
statistical analysis of data sets. Analysis of variance (ANOVA) was employed to analyse 206 
fixed effects on different traits with various post-hoc tests as detailed in figure legends. A p 207 
value < 0.05 was considered statistically significant. 208 
Results  209 
Design and quality control of particulate vaccines 210 
Adilipoline adjuvanted chitosan-based particulate formulations of PRRSV antigens were 211 
prepared as illustrated in Figure 1A. The first formulation was made by encapsulating 212 
inactivated PRRSV-1 Olot/91 (Virus-P). Inactivated virus served as a crude and diverse 213 
mixture of antigens, which may be recognised by both B and T cells. This formulation was 214 
adjuvanted by encapsulation of and coating with Adilipoline. The second formulation was 215 
similarly adjuvanted but particles encapsulated synthetic peptides representing the M and 216 
NSP5 proteins, as T cell antigens, and were coated with a recombinant M/GP5 fusion protein 217 
fragment (EM4) possessing a non-neutralising antibody epitope, which served as a model B 218 
cell antigen (Peptide-P). The third formulation, which served as the negative control, 219 
consisted of empty chitosan particles (Empty-P). Scanning electron microscopy showed 220 
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particles with a spherical morphology and a typical diameter less than 5µm (Figure 1B). The 221 
Virus-P tended to be larger and to collapse more easily, possibly due to the volume of antigen 222 
encapsulated. Zeta potential measurements showed the Virus-P to be negatively charged 223 
whereas the Peptide-P and Empty-P were positively charged, which most likely reflected 224 
their differing composition (Figure 1C).  225 
To assess the efficiency of virus or peptide encapsulation and coating with EM4 protein, 226 
antigen was quantified in particle-free supernatants (Supplementary Figure S1). Inactivated 227 
PRRSV Olot/91 and EM4 were assessed using antigen-capture ELISAs and the encapsulation 228 
efficiencies were calculated to be over 99% efficient. The adsorption of EM4 protein onto the 229 
surface of ~80% of Peptide-P was additionally demonstrated by flow cytometry 230 
(Supplementary Figure S2). Given the high efficiency of EM4-coating, a fluorometric 231 
biochemical assay was conducted to assess the encapsulation of M and NSP5 peptides which 232 
were be estimated to be at >98% efficient (Supplementary Figure S1). Assessment of 233 
Adilipoline incorporation was not undertaken as it was not readily amenable to assessment by 234 
ELISA or other means e.g. HPLC.    235 
The particles were screened in vitro to assess the cytokine response profiles of blood DCs and 236 
monocytes (Figure 2). Cultures of enriched blood DCs, which included both plasmacytoid 237 
and conventional DC subsets (Franzoni et al., 2014), and monocytes were cultured in the 238 
presence of titrations of particle formulations, which for Peptide- and Virus-P were 239 
additionally tested with (‘washed’) and without (‘unwashed’) pre-washing to potentially 240 
remove any unbound Adilipoline. Unstimulated and soluble Adilipoline stimulation 241 
conditions were included as negative and positive controls, respectively. Statistically 242 
significant IL-8 responses from DCs and monocytes were induced by both the washed and 243 
unwashed adjuvanted particles. Interestingly, Empty-P also induced an IL-8 response from 244 
monocytes, albeit of a lesser magnitude than the adjuvanted particles, but this was not 245 
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detectable in DC cultures. No IL-10 was detected in supernatants from DC cultures and only 246 
Virus-P induced a statistically significant monocyte IL-10 response, suggestive that this was 247 
virus- rather than Adilipoline-specific. Whilst not detected in monocyte cultures, statistically 248 
significant IL-12 and type I IFN responses were detected in DC cultures following 249 
stimulation with both Virus- and Peptide-P, irrespective of washing, suggesting that particle-250 
associated Adilipoline was inducing these responses.  251 
Assessment of immune responses and protection following experimental vaccination in 252 
pigs 253 
Groups of pigs (n=6) were vaccinated twice with each of the particulate formulations (Virus-254 
P, Peptide-P and Empty-P) with a three week interval between prime and booster 255 
inoculations. After a further three weeks, all animals were challenged with a UK field strain 256 
of PRRSV-1 (215-06) and assessed for protection. Over the duration of the experiment, the 257 
induction of antigen-specific antibody and T cell responses were monitored and protection 258 
assessed by measuring viraemia by quantitative RT-PCR. 259 
Assessment of PRRSV-specific antibody responses using a commercial N protein-based 260 
ELISA showed that after the booster immunization, significant levels of specific antibodies 261 
were detected in the Virus-P immunised group (Figure 3A). These responses were rapidly 262 
boosted by challenge infection and were significantly greater than the Peptide- and Empty-P 263 
groups on days 7 and 14 post-challenge). Significant EM4-specific antibody responses were 264 
detected in the Peptide-P immunised group from day 28 (7 days post booster immunisation) 265 
which remained elevated for the duration of the study (Figure 3B). As expected for this 266 
subdominant epitope there was little evidence of further boosting of this response upon the 267 
challenge infection and levels remained low in the Virus- and Empty-P groups. Assessment 268 
of virus-neutralising antibodies in serum samples revealed only two pigs from the Virus-P 269 
immunised group with low ND50 titres of 4 (pig 12) and 11 (pig 15) (data not shown).  270 
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Following in vitro stimulation of PBMC with PRRSV-1 Olot/91, M and NSP5 peptides, IFN-271 
γ and TNF-α co-expression by CD4 and CD8 T cells was assessed by flow cytometry. Single 272 
cytokine producing cells were also assessed however very few single cytokine expressing 273 
cells were identified and therefore only data for dual-cytokine expressing cells are presented 274 
(Figure 4). Post-vaccination, the only significant responses detected were M and NSP5-275 
specific CD4 T cells responses from 3/6 Peptide-P immunised pigs and virus-specific CD4 T 276 
cells responses from an individual animal in each of the Peptide-P and Virus-P immunised 277 
groups. Significant responses were detected in all groups post-challenge: the majority of pigs 278 
in each group mounted both CD4 and CD8 T cell responses to M peptides and PRRSV. 279 
NSP5-specific CD4 T cell responses were detected in one of the Virus-P immunised pigs and 280 
four of the Peptide-P immunised pigs.  2/6 Virus-P, 3/6 Peptide-P and 4/6 Empty-P 281 
immunised pigs displayed significant NSP-5 specific CD8 T cell responses.  282 
Three weeks after the booster immunisation, all pigs were challenged intranasally with 283 
PRRSV-1 215-06 and the course of RNAemia assessed by RT-qPCR (Figure 5). PRRSV 284 
RNA levels peaked in animals regardless of vaccination group on day 7 post-challenge with 285 
the highest levels detected in the Peptide-P immunised group. Levels declined thereafter with 286 
the lowest levels detected in the Peptide-P group albeit without statistical significance. 287 
Upon termination of the experiment, day 21 post-challenge, lungs were lavaged post-mortem. 288 
The BALF cellularity and composition was determined, and T cell responses measured 289 
following stimulation with PRRSV or a pool of M/NSP5 peptides (Figure 6).  For technical 290 
reasons it was not possible to collect BALF from all animals. The results showed that for all 291 
animals irrespective of vaccine group there was a significantly greater number of CD8 292 
compared to CD4 T cells within the lavage fluid. Assessment of antigen-specific responses 293 
showed that again for all animals there was a statistically significantly higher frequency of 294 
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PRRSV and M/NSP5 specific CD8 T cells compared to CD4. The frequency of antigen-295 
specific CD8 T cells in BALF was much higher than had been detected in blood (Figure 5). 296 
Discussion 297 
The results of this study have shown that hydrophobically-modified chitosan may be used to 298 
efficiently generate particulate formulations of either whole PRRSV or defined PRRSV 299 
antigens. Further enhancement of the immunostimulatory nature of these particles by co-300 
formulation with the multi-PRR ligand Adilipoline was demonstrated in vitro. However, 301 
despite the encouraging in vitro data, vaccination with these formulations induced antibody 302 
responses but failed to induce strong antigen-specific T cell responses, which are believed to 303 
be required for the effective control of PRRSV infection in the absence of neutralising 304 
antibodies (Morgan et al., 2013; Murtaugh and Genzow, 2011; Weesendorp et al., 2013; 305 
Zuckermann et al., 2007). It is worthy to note that the Peptide-P formulation appeared to 306 
prime at least in half the animals CD4 as opposed to CD8 T cell responses. The data from the 307 
lung lavages following the resolution of the PRRSV infection was striking and would further 308 
suggest that it was a lack of CD8 T cell response that may underlie the poor vaccine efficacy 309 
observed. The vaccine formulations did result in cross-presentation of antigen to memory 310 
CD8 T cells in vitro, albeit with a lower efficiency than to CD4 T cells (data not shown). 311 
Several factors may underlie the poor T cell immunogenicity of these particles including the 312 
choice of polymer, the size of the particles and the quantity of antigen/adjuvant loaded. 313 
Chitosan was selected as the polymer core of the particulate vaccines due to its inherent 314 
immunostimulatory properties (Highton et al., 2015; Zaharoff et al., 2007; Zhu et al., 2007), 315 
which is thought to be mediated through engagement of TLR4 and mannose receptors on 316 
antigen-presenting cells (Villiers et al., 2009).  Rather unexpectedly, the results of the in vitro 317 
evaluation of our chitosan particles showed that non-adjuvanted particles failed to induce 318 
cytokine responses from porcine DCs and elicited only an IL-8 response from monocytes. 319 
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The formulated particles in the present study were in the low micron range, which is at the 320 
upper range of optimal particle size for phagocytosis by DCs and macrophages (He et al., 321 
2010; Thiele et al., 2001). Whilst outside the scope of the present study, formulation 322 
conditions may be manipulated to create antigen encapsulated chitosan particles with discrete 323 
nominal sizes. A recent study of chitosan particles of 300nm, 1µm, and 3µm parameters  324 
showed that 1μm particles were optimal for phagocytosis by macrophages but uptake by DC 325 
was independent of particle size (Koppolu and Zaharoff, 2013). Interestingly the three 326 
particle sizes induced discrete DC cytokine response profiles and the 3μm particles were best 327 
at stimulating antigen-presentation and CD4 T cell responses; which was attributed to 328 
augmented antigen encapsulation efficiency (Koppolu and Zaharoff, 2013). In the present 329 
study, we indirectly assessed the formulated antigen cargo by quantifying antigen that 330 
remained in supernatants following formulation. Whilst these analyses suggested very high 331 
(>90%) encapsulation and coating efficiencies, in line with previous studies (Koppolu and 332 
Zaharoff, 2013; Li et al., 2008; Oliveira et al., 2012), assessment of entrapped antigen 333 
following chitinase digestion may have verified whether the antigens had maintained their 334 
stability upon encapsulation. Presumably due to Adilipoline engagement with TLR-7, 335 
adjuvanted formulations also induced significant IL-12 and IFN-α responses from DC, which 336 
are both reported to drive cross-presentation and induction of CD8 T cell responses (Janssen 337 
and Thacker, 2012; Joffre et al., 2012; Oh et al., 2011). The XCR1+ conventional DC subset 338 
(cDC1) is highly efficient at cross-presenting exogenous antigen to CD8+ T cells  and mice 339 
lacking XCR1 or its ligand, are less able to cross-present antigen necessary for induction of 340 
CD8+ T cell responses against viruses and intracellular bacteria (Fries, 2016; Shortman and 341 
Heath, 2010). Further work should therefore address how efficiently chitosan particles are 342 
taken up and processed by porcine cCD1, since enhancing the targeting and activation of this 343 
DC subset could be crucial to enhancing CD8 T cell induction in vivo.  344 
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Another factor which needs to be considered in the future is the route of inoculation. In 345 
contrast to peripheral blood where both CD4 and CD8 T cell responses were detected, the 346 
virus and M/NSP5 specific response in the lung were almost exclusively from CD8 T cells 347 
and this was accompanied by a greater infiltrate of these cells compared to CD4 T cells. 348 
These data support earlier observations (Samsom et al., 2000) and suggest that the CD8 T cell 349 
population performs a critical role in the effector phase of the immune response in clearing 350 
virus from the lungs. While the subcutaneous route ensured efficient delivery of the vaccine 351 
in vivo, recent studies have shown that targeting DCs at mucosal sites is crucial to programme 352 
mucosa-homing T cell responses (Mikhak et al., 2013; Sandoval et al., 2013). This is 353 
supported by the recent reports that intranasal delivery of an adjuvanted PLGA based 354 
nanoparticulate formulation of crude PRRSV antigens protected against heterologous 355 
challenge infection (Binjawadagi et al., 2014a; Binjawadagi et al., 2014b).  The inherent 356 
mucoadhesive properties of hydrophobic chitosan (Patel et al., 2010) makes this a viable 357 
proposal for investigating the induction of mucosal immunity which may be required for 358 
protection against PRRSV and intranasal or aerosol immunisation should be considered in 359 
future work.  360 
Alternatives to particulate delivery should also be considered for induction of CD8 T cell 361 
responses against M and NSP5. The use of viral vectors such as recombinant replication-362 
deficient adenovirus or pox virus vectors are the subject intense investigation for the 363 
development of vaccines to T cell responses against a range of  intracellular pathogens (Ertl, 364 
2016; Sebastian and Gilbert, 2016). However, another viral vector system that warrants 365 
consideration for induction of T cell immunity is the use of cytomegaloviruses (CMV). The 366 
capacity of CMV-based vaccines to induce T cell responses against virulent pathogens 367 
entering via mucosal sites as was most strikingly demonstrated by the prevention of lethal 368 
simian immunodeficiency virus (SIV) infection in rhesus macaques following challenge of 369 
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animals vaccinated with rhesus CMV (RhCMV)-based vectors expressing SIV antigens 370 
(Hansen et al., 2011). Porcine CMV (PCMV) in pigs appears comparable to CMV infection in 371 
other species. Although PCMV remains poorly characterised in immunological terms compared 372 
to other CMVs (mouse, rhesus macaque and human), the CMV-specific immune response is 373 
remarkably conserved between different CMV species, strongly suggesting that PCMV will have 374 
similar immunological characteristics. The annotated PCMV genome was recently published (Gu 375 
et al., 2014), which makes the design and construction of PCMV-based vectors expressing 376 
PRRSV M and NSP5 possible for the first time.  377 
In conclusion, this study has provided further data to support PRRSV M and NSP5 as vaccine 378 
candidate T cell antigens. The biomimetic particulate formulations showed promising initial 379 
results and whilst immunogenicity may be readily improved by virtue of being a highly 380 
customisable mode of formulation, delivery of M and NSP5 by live viral vectors should also 381 
be explored. 382 
ACKNOWLEDGEMENTS 383 
The authors thank Sonia Zúñiga Lucas and Luis Enjuanes, Centro Nacional de Biotecnología, 384 
Madrid, Spain, for supplying the PRRSV-1 Olot/91 strain; Kirsten Morris, CSIRO 385 
Biosecurity Flagship, Australian Animal Health Laboratory, Geelong, Australia for provision 386 
of recombinant porcine IL-3; Derek Clifford and APHA Animal Services Unit for the care of 387 
animals and provision of samples; and Bill Cooley and Alex Nunez, APHA Pathology 388 
Department for assistance with scanning electron microscopy and post-mortems. This work 389 
was supported by the PoRRSCon Project of the European Union Seventh Framework 390 
Programme (Grant # 245141), Project SE0529 from the UK Department for the Environment, 391 
Food and Rural Affairs, and APHA Research and Development Internal Investment Fund 392 
Project RD0081.  393 
 394 
17 
 
CONFLICT OF INTEREST STATEMENT 395 
The authors declare no conflict of interest. 396 
 397 
FIGURE LEGENDS 398 
Figure 1. Formulation of PRRSV antigens in adjuvanted hydrophobic chitosan 399 
particles. Schematic representation of the three particulate formulations: (1) Adilipoline-400 
adjuvanted chitosan particles entrapping inactivated PRRSV-1 Olot/91 (Virus-P), (2) 401 
Adilipoline-adjuvanted chitosan particles entrapping PRRSV-1 M and NSP5 peptides and 402 
coated in PRRSV-1 EM4 protein (Peptide-P) and (3) empty chitosan particles (Empty-P) (A). 403 
Assessment of particle morphology and size by SEM (B). Representative SEM micrographs 404 
of each of the particulate formulations (Batch 2 – booster preparation) with scale bars 405 
indicating that the diameter of the majority of particles was in the low micrometre range. The 406 
surface charge of the three particle formulations prepared for the prime (Batch 1- filled bars) 407 
and booster (Batch 2 – open bars) immunisations were assessed by zeta potential 408 
measurements (C). Results presented are the mean of triplicate measurements of the same 409 
sample and error bars represent SEM. The means were compared using a one-way ANOVA 410 
followed by a Dunnett’s multiple comparison test; ****p < 0.0001 and ***p < 0.001. 411 
Figure 2. Assessment of the cytokine response profiles from porcine DCs and monocytes 412 
pulsed with vaccine particle formulations. Cultures of enriched blood DCs and monocytes 413 
were cultured for 18 hours in the presence of titrations of particle formulations (particle: cell 414 
ratios from 10:1 - 0.3:1).  Both Peptide- and Virus-P were tested with (‘washed’) and without 415 
(‘unwashed’) washing to remove unbound Adilipoline. No stimulation and soluble 416 
Adilipoline were included as negative and positive controls, respectively. After incubation, 417 
the levels of IL-8, IL-10, IL-12 and type I IFN were quantified in cell-free culture 418 
supernatants by cytokine ELISA or bioassay. The results presented are the mean unstimulated 419 
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corrected values from triplicate cultures and error bars represent SEM. Log transformed 420 
cytokine responses of adjuvanted particles were compared against the Empty-P using a 2-way 421 
ANOVA with Dunnett’s multiple comparison test; statistically significant differences are 422 
indicated as: ‘a’ - unwashed Virus-P; ‘b’ - washed Virus-P; ‘c’ - unwashed Peptide-P; and ‘d’ 423 
- washed Peptide-P. 424 
Figure 3. Assessment of PRRSV and EM4 specific serum antibody responses following 425 
vaccination and challenge. Longitudinal serum samples were analysed for PRRSV specific 426 
antibody using a commercial PRRSV N-protein based ELISA (A) and assessed for EM4-427 
specificity using an in-house ELISA (B). Data presented are the mean ELISA OD values for 428 
each group (n=6) and error bars represent SEM. Responses of each group were compared 429 
against using a 2-way ANOVA with Dunnett’s multiple comparison test; statistically 430 
significant differences between the responses of Virus-P immunised pigs and Empty-P 431 
immunised pigs are indicated as ‘a’ whereas significant differences between Peptide-P and 432 
Empty-P immunised pigs are indicated as ‘b’. The timings of booster immunisation and 433 
PRRSV-1 challenge infection are indicated. 434 
Figure 4. Assessment of PRRSV, M and NSP5 specific T cell cytokine responses post-435 
vaccination and challenge. Longitudinally collected PBMC were stimulated in vitro with 436 
peptides representing the PRRSV M and NSP5 proteins or with live PRRSV Olot/91. IFN-γ 437 
and TNF-α co-expression by CD4 (open symbols) and CD8 (closed symbols) T cells was 438 
assessed using flow cytometry (A). Data represent the mean background corrected response 439 
for each group (n=6) ± SEM. Responses of each group were compared against using a 2-way 440 
ANOVA with Dunnett’s multiple comparison test; statistically significant differences 441 
between the responses of Virus-P immunised pigs and Empty-P immunised pigs are indicated 442 
as ‘a’ whereas significant differences between Peptide-P and Empty-P immunised pigs are 443 
indicated as ‘b’. The timings of booster immunisation and PRRSV-1 challenge infection are 444 
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indicated as ‘B’ and ‘C’, respectively. Antigen-specific cytokine responses of individual 445 
animals were also assessed by comparing responses against those measured pre-vaccination 446 
and the proportion of animals mounting significant T cell responses post-vaccination and 447 
post-challenge are presented (B).  448 
Figure 5. Assessment of viraemia post-challenge by intranasal inoculation with PRRSV-449 
1. Serum samples were longitudinally collected post-challenge with PRRSV-1 field isolate 450 
215-06 and PRRSV RNA assessed by quantitative RT-PCR. Data are presented as the mean 451 
PRRSV ORF7 copy numbers for each group (n=6) ± SEM. Responses of each group were 452 
compared using a 2-way ANOVA with Dunnett’s multiple comparison test; statistically 453 
significant differences between Peptide-P and Empty-P immunised pigs are indicated as ‘b’.  454 
Figure 6. Assessment of antigen-specific lung T cell responses following intranasal 455 
challenge with PRRSV-1. Twenty one days after challenge PRRSV-1 strain 215-06, T cells 456 
in BALF were phenotyped and enumerated by volumetric flow cytometry (A). Isolated cells 457 
were stimulated in vitro with PRRSV (virus) or a pool of M and NSP5 peptides (peptide). 458 
IFN-γ and TNF-α expression by CD4 and CD8 T cells was assessed by flow cytometry (B). 459 
Data represent the mean responses of animals in each group from which lavage fluid could be 460 
collected without contaminating blood cells (Virus-P n=5; Peptide-P n=1; Empty-P n=6), 461 
with bars representing SEM. Differences between CD4 and CD8 responses from all animals 462 
were compared using a one-way ANOVA followed by a Dunnett’s multiple comparison test; 463 
***p < 0.001 and **p < 0.01. 464 
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Supplementary Figure S1.  Assessment of inactivated PRRSV-1, EM4 and 672 
peptide incorporation into particle formulations. The presence of inactivated 673 
PRRSV-1 (Virus) (A) and EM4 protein (B) in particle-free supernatants were assessed 674 
by antigen-capture ELISAs. The presence of M and NSP5 peptides in particle-free 675 
supernatants was assessed by fluorometric OPA assay (C). Representative standard 676 
curves for each assay (left column) are presented as are the mean triplicate values of 677 
titrations of particle supernatants from preparations formulated for prime and boost 678 
immunisations and error bars represent SEM (right column). 679 
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Supplementary Figure S2. Assessment of EM4 coating of chitosan particle 683 
formulations by flow cytometry. The absorption of EM4 protein onto the surface of 684 
chitosan particles was assessed by staining particles with a specific mAb and 685 
visualisation by staining with a fluorochrome labelled secondary antibody. 686 
Representative dot plots are shown of the forward and side scatter properties of each 687 
of the three particle formulations and their staining following incubation with isotype 688 
control or EM4 specific mAbs (A). The percentage of particles falling into the positive 689 
staining gate are graphically presented in panel B. 690 
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Supplementary Materials and Methods 692 
 693 
Assessment of the antigen loading efficiency  694 
 695 
Aliquots of each particle formulation were centrifuged at 14000rpm for 5 min and 696 
supernatants were harvested and stored at -80°C until analysed. ELISA and 697 
biochemical assay analyses of particle-free supernatants were conducted to 698 
determine the efficiency of virus or peptide encapsulation and coating with EM4 699 
protein. Absorption of EM4 to particle surfaces was additionally assessed by flow 700 
cytometric staining and analyses of particles. 701 
EM4 protein in particle-free supernatants was assessed by ELISA. ELISA plates 702 
(MAXISorb, Nunc, Fisher Scientific, Loughborough, UK) were coated (100µl/well) 703 
overnight at 4°C with titrations of particle-free supernatants from Peptide- and Empty-704 
P formulations in carbonate-bicarbonate buffer. Recombinant EM4 protein was 705 
included as a standard. Plates were washed, blocked PBS, 0.05% Tween, 5% BSA, 706 
and incubated with 1 µg/ml anti-EM4 mAb (Clone EM11E10, Ingenasa, Madrid Spain). 707 
After 1 h incubation at room temperature, plates were washed and incubated with 708 
rabbit-anti-mouse IgG-HRP antibody (Dako, Ely, UK) 1h at room temperature. 709 
Subsequently, plates were washed, incubated with TMB substrate (Sigma-Aldrich) for 710 
a maximum of 10 min in the dark before the reaction was stopped with 0.5M H2SO4 711 
and absorbance at 450nm read on a Victor4 microplate reader (Perkin Elmer, Seer 712 
Green, UK). ELISA quantification of inactivated PRRSV-1 in particle-free supernatants 713 
was performed as described above with the following modifications: plates were 714 
coated with particle-free supernatants from Virus- and Empty-P formulations; 715 
inactivated PRRSV Olot/91 was used as a standard; antigen was detected using anti-716 
PRRSV N protein mAb clone 1AC7 at 10µg/ml (Ingenasa). To quantify peptides in 717 
particle-free supernatants the biochemical fluorometric o-phthalaldehyde (OPA) assay 718 
was performed according to manufacturer’s instructions (Fluoraldehyde (OPA) 719 
Reagent Solution, Thermo Scientific, UK) with minor modifications: particle-wash 720 
supernatants from Peptide- and Empty-P formulations were serially diluted two-fold in 721 
water; a pool of M and NSP5 peptides was used as a standard; 20µl of samples or 722 
standards were mixed with 200 µl of Fluoraldehyde Reagent Solution in black 96 well 723 
microplates (OptiPlate; PerkinElmer) and fluorescence read immediately on a Victor4 724 
32 
 
microplate reader using excitation and emission wavelengths of 340 and 455nm, 725 
respectively.  726 
To assess absorption of EM4 protein to particles by flow cytometry, particles were 727 
washed twice in PBS and stained 1µg/ml anti-EM4 mAb (E10C7) or isotype control 728 
IgG2b antibody (AbD Serotec, Oxford, UK) for 30 min at 4oC. After two washes in 729 
particles were stained with anti-mouse IgG2-PE conjugated secondary antibody (BD 730 
Biosciences) and incubated as before. After a final two washes, particles were 731 
analysed on a MACSQuant Analyzer flow cytometer (Miltenyi Biotec, Bisley, UK). 732 
Particles were gated by forward and side scatter measurements with logarithmic 733 
scaling. EM4 staining was assessed by setting a gate based on isotype control mAb 734 
staining. 735 
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